Lifecare AS (DE:LFC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Lifecare ASA has reported a successful nine-week longevity trial of its Sencell sensor, a next-gen Continuous Glucose Monitor (CGM) system, showing operational viability beyond two months in a live dog. The study confirms both the sensor’s functionality and biocompatibility, with no negative reactions observed. Excited about these real-world results, Lifecare ASA is planning to extend the study, potentially doubling the implant period, and is preparing to enroll more subjects to validate the findings.
For further insights into DE:LFC stock, check out TipRanks’ Stock Analysis page.
